EBITDA: Income before interest, taxes, depreciation and amortization.
VYNE Therapeutics Inc. (VYNE) had EBITDA of $-3.83M for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
$0.09M |
|
$-3.58M |
|
-- |
|
$0.09M |
|
$3.90M |
|
$-3.82M |
|
$0.23M |
|
$-3.58M |
|
$-3.58M |
|
$-3.58M |
|
$-3.58M |
|
$-3.58M |
|
$-3.58M |
|
$-3.82M |
|
|
EBITDA |
$-3.83M |
42.77M |
|
42.77M |
|
$-0.08 |
|
$-0.08 |
|
| Balance Sheet Financials | |
$25.79M |
|
$0.08M |
|
$0.08M |
|
$25.87M |
|
$1.24M |
|
-- |
|
-- |
|
$1.24M |
|
$24.64M |
|
$24.64M |
|
$24.64M |
|
33.35M |
|
| Cash Flow Statement Financials | |
$-4.08M |
|
$4.70M |
|
$-0.01M |
|
$24.03M |
|
$24.63M |
|
$0.60M |
|
$0.47M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
20.86 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-4437.21% |
|
-4437.21% |
|
-- |
|
-4168.60% |
|
-4168.60% |
|
$-4.08M |
|
-- |
|
-- |
|
-- |
|
0.00 |
|
-- |
|
-- |
|
-- |
|
-14.55% |
|
-14.55% |
|
-13.86% |
|
-14.55% |
|
$0.74 |
|
$-0.10 |
|
$-0.10 |
|